98%
921
2 minutes
20
Background: The clinical implications of chronic kidney disease (CKD) and cardiac sympathetic nervous activity (CSNA) regarding lethal arrhythmic events have not yet been fully elucidated in patients with chronic heart failure (CHF). We hypothesized that the combination of CKD and abnormal CSNA, assessed by I-metaiodobenzylguanidine ( I-MIBG) scintigraphy, may provide useful prognostic information for lethal arrhythmic events.
Methods: We studied 165 consecutive hospitalized CHF patients without dialysis. Cardiac I-MIBG scintigraphy was performed in a clinically stable condition, and abnormal CSNA was defined as a late heart-to-mediastinum ratio of <1.6. CKD was defined as an estimated glomerular filtration rate of <60 ml/min/1.73 m . We then investigated the incidence of lethal arrhythmic events (sustained ventricular tachyarrhythmia, appropriate implantable cardioverter-defibrillator therapy, or sudden cardiac death).
Results: During a median follow-up of 5.3 years, lethal arrhythmic events were observed in 40 patients (24.2%). The patients were divided into four groups according to the presence of CKD and CSNA abnormality: non-CKD/normal CSNA (n = 52), CKD/normal CSNA (n = 39), non-CKD/abnormal CSNA (n = 33), and CKD/abnormal CSNA (n = 41). Kaplan-Meier analysis showed that CKD/abnormal CSNA had the highest event rate (log-rank p = .004). Additionally, the Cox proportional hazard analysis revealed that CKD/abnormal CSNA was a predictor for lethal arrhythmic events compared with non-CKD/normal CSNA (hazard ratio, 5.368, p = .001). However, the other two groups did not show significant differences compared with the non-CKD/normal CSNA group.
Conclusions: The combination of CKD and abnormal CSNA, assessed by I-MIBG scintigraphy, had a high predictive value for lethal arrhythmic events in patients with CHF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739613 | PMC |
http://dx.doi.org/10.1111/anec.12900 | DOI Listing |
Europace
August 2025
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Aims: A decline in left ventricular ejection fraction (LVEF) is often observed in patients with heart failure with preserved ejection fraction (HFpEF) and is associated with adverse outcomes. Although baseline LVEF is crucial for assessing the risk of sudden cardiac death in patients with HF, little is known about the relationship between the decline in LVEF and lethal arrhythmic events among patients with HFpEF.
Methods And Results: We retrospectively analysed data from the CHART-2 Study.
Nat Cardiovasc Res
July 2025
Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, MD, USA.
Sudden cardiac death from ventricular arrhythmias is a leading cause of mortality worldwide. Arrhythmic death prognostication is challenging in patients with hypertrophic cardiomyopathy (HCM), a setting where current clinical guidelines show low performance and inconsistent accuracy. Here, we present a deep learning approach, MAARS (Multimodal Artificial intelligence for ventricular Arrhythmia Risk Stratification), to forecast lethal arrhythmia events in patients with HCM by analyzing multimodal medical data.
View Article and Find Full Text PDFBr J Pharmacol
September 2025
Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Background And Purpose: Torsades de pointes is a potentially lethal ventricular arrhythmia that can be induced by many classes of drugs. The risk for a given drug depends upon the combination of cardiac ion channels that it targets. The axis of arrhythmia quantifies that risk.
View Article and Find Full Text PDFJACC Case Rep
May 2025
Department of Cardiology, Hammersmith Hospital, Imperial College Healthcare Trust, London, United Kingdom.
Background: Mitral valve prolapse (MVP) is the most common valvular heart disease and historically was considered benign in the absence of severe mitral regurgitation and normal left ventricular function. However, an emerging subset associated with sudden cardiac death that does not follow traditional risk stratification has been established termed the arrhythmic mitral valve prolapse (A-MVP) syndrome. This cohort provide a clinical challenge on identifying those at risk of lethal arrhythmias who may benefit from a primary prevention implantable cardiac defibrillator.
View Article and Find Full Text PDFG Ital Cardiol (Rome)
June 2025
Centro per lo Studio e la Cura delle Aritmie Cardiache di Origine Genetica, Istituto Auxologico Italiano IRCCS, Milano.
The long QT syndrome (LQTS) is a cardiac disease of genetic origin which, unless properly diagnosed and managed, carries a high risk for sudden cardiac death, especially among youngsters. At the same time, the available therapies are quite effective. Most lethal episodes occur as the sentinel event, stressing the fact that most of the time there is no room for error in diagnosis or management.
View Article and Find Full Text PDF